The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Evolving treatment strategies at first relapse in follicular lymphoma
Bradley Hunter, MD, Intermountain Healthcare, Salt Lake City, UT, discusses how treatment decisions at first relapse in follicular lymphoma have evolved with the introduction of novel therapies. He highlights data showing that epcoritamab with rituximab plus lenalidomide (R²) can substantially delay the need for subsequent treatment and notes that this fixed-duration regimen may be suitable for delivery in community oncology settings.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties worldwide. All rights are reserved.
